Subject:
- Active Substance: Faricimab
- Name: Vabysmo®
- Therapeutic area: Visual impairment due to diabetic macular edema (DME)
- Pharmaceutical company: Roche Pharma AG
Time table:
- Start: 15.10.2022
- Publication of assessment: 16.01.2023
- End of public hearing: 06.02.2023
- Final decision by G-BA: beginning of April 2023
Comparative therapy:
- Ranibizumab or aflibercept